A [‐2]proPSA‐based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases
- 21 October 2008
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 69 (2) , 198-207
Abstract
Background: The aim of this study was to combine the new automated Access [‐2]proPSA (p2PSA) assay with a percent free PSA (%fPSA) based artificial neural network (ANN) or logistic regression (LR) model to enhance discrimination between patients with prostate cancer (PCa) and with no evidence of malignancy (NEM) and to detect aggressive PCa.Methods: Sera from 311 PCa patients and 275 NEM patients were measured with the p2PSA, total PSA (tPSA) and free PSA (fPSA) assays on Access immunoassay technology (Beckman Coulter, Fullerton, CA) within the 0–30 ng/ml tPSA range. Four hundred seventy‐five patients (264 PCa, 211 NEM) had a tPSA of 2–10 ng/ml. LR models and leave‐one‐out (LOO) ANN models with Bayesian regularization by using tPSA, %fPSA, p2PSA/fPSA (%p2PSA), age and prostate volume were constructed and compared by receiver‐operating characteristic (ROC) curve analysis.Results: The ANN and LR model each utilizing %p2PSA, %fPSA, tPSA and age, but without prostate volume, reached the highest AUCs (0.85 and 0.84) and best specificities (ANN: 62.1% and 45.5%; LR: 53.1% and 41.2%) compared with tPSA (22.7% and 11.4%) and %fPSA (45.5% and 26.1%) at 90% and 95% sensitivity. The %p2PSA furthermore distinguished better than tPSA and %fPSA between pT2 and pT3, and Gleason sum <7 and ≥7 PCa.Conclusions: The automated p2PSA assay offers a new tool to improve PCa detection, and especially aggressive PCa detection. Incorporation of %p2PSA into an ANN and LR model further enhances the diagnostic accuracy to differentiate between malignant and non‐malignant prostate diseases. Prostate 69: 198–207, 2009. © 2008 Wiley–Liss, Inc.Keywords
This publication has 40 references indexed in Scilit:
- [-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation StudyJournal of Urology, 2008
- New Insights Into the Diagnostic Accuracy of Complexed and Total Prostate Specific Antigen Using Discordance Analysis CharacteristicsJournal of Urology, 2006
- Pro PSA : a “pro cancer” form of PSA?Medical Hypotheses, 2005
- A MULTICENTER CLINICAL TRIAL ON THE USE OF (–5, –7) PRO PROSTATE SPECIFIC ANTIGENJournal of Urology, 2005
- Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detectionBJU International, 2005
- REporting recommendations for tumour MARKer prognostic studies (REMARK)European Journal of Cancer, 2005
- Proenzyme Forms of Prostate-Specific Antigen in Serum Improve the Detection of Prostate CancerClinical Chemistry, 2004
- The value of (−7, −5)pro‐prostate‐specific antigen and human kallikrein‐2 as serum markers for grading prostate cancerBJU International, 2004
- Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/MlJournal of Urology, 2003
- An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigationInternational Journal of Cancer, 2002